الفهرس 
Epidemiology of Breast CancerOnly 14 pages are availabe for public view
 |  | from | 397 |  |  |
| | | from | 397 | | |
Abstract
Metformin, a widely prescribed oral hypoglycemic agent, has recently received increased attention because of its potential antitumorigenic effects in different cancer types. The present study investigated the impact of adding metformin to breast cancer adjuvant therapy in nondiabetic women on, insulin like growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), insulin, fasting blood glucose (FBG), the molar ratio of IGF-1 to IGFBP-3, homeostatic model assessment of insulin resistance (HOMA-IR) and metastasis.